{"schema_version":"secwatch.filing_event.v1","accession":"0001672688-25-000082","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.108176+00:00","generated_at":"2026-05-16T21:18:37.092528+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Absci Reports Q3 2025 Results, Advances ABS-201 and ABS-101 Programs","bullets":["Reported interim Phase 1 data for ABS-101 (anti-TL1A) showing extended half-life with no serious adverse events.","Accelerated initiation of Phase 1/2a trial for ABS-201 in androgenetic alopecia to December 2025.","Expanding ABS-201 strategy to endometriosis, targeting Phase 2 start in Q4 2026 and proof-of-concept in H2 2027.","Cash, cash equivalents, and marketable securities totaled $152.5 million as of Sept 30, 2025, funding operations into H1 2028.","Net loss was $28.7 million for Q3 2025, compared to $27.4 million in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001672688-25-000082","json":"https://secwatch.observer/filing/0001672688-25-000082.json","markdown":"https://secwatch.observer/filing/0001672688-25-000082.md","text":"https://secwatch.observer/filing/0001672688-25-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/0001672688-25-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/absc-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T21:18:37.092528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}